The Serum Levels of the Soluble Factors sCD40L and CXCL1 Are Not Indicative of Endometriosis

Pateisky, Petra; Pils, Dietmar; Kuessel, Lorenz; Szabo, Ladislaus; Walch, Katharina; Obwegeser, R.; Wenzl, René; Yotova, Iveta

doi:10.1155/2016/2857161

Cited by 7 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, CXCL1 was considered as a predictor of ovarian cancer response to chemotherapy. Similarly to our study, it was also reported that the serum level of CXCL1 was not increased in endometriosis patients [ 35 ]. It is known that CXCL1 exerts multiple effects directly on the cancer cells as well as on stromal cells such as fibroblasts and immune cells promoting tumor development, progression, and metastasis [ 2 ].…”

Section: Discussionsupporting

confidence: 89%

Chemokine expression in patients with ovarian cancer or benign ovarian tumors

Nowak

Janas²,

Soja³

et al. 2021

Arch Med Sci

View full text Add to dashboard Cite

IntroductionChemokines play a crucial role in tumor growth and progression according to proangiogenic and immunosuppressive acting. This study was aimed to investigate the serum levels of selected chemokines in patients with ovarian cancer or benign ovarian tumors to point on their role in tumorigenesis and their potential use in preoperative diagnosing of adnexal mass.Material and methodsThe study group consisted of 59 women with ovarian cancer: 17 epithelial ovarian cancer (EOC) patients and 42 women with benign ovarian tumors. We measured in sera obtained preoperatively the level of CA125 and the panel of 5 chemokines: CX3CL1/Fractalkine, CXCL1/GRO-α, CXCL12/SDF-1, CCL20/MIP-3α and IL-17F, using chemiluminescence method with multiplexed bead based immunoassay.ResultsCX3CL1 was significantly elevated in sera of advanced ovarian cancer patients compared to women with benign ovarian tumors. The significant elevation of CXCL1 was also observed (both: early and advanced stage). The similar pattern was present with standard ovarian cancer marker – CA125. In our patients with endometriotic cysts CA125 levels were significantly higher than in women with other benign tumors whereas all analyzed chemokines had similar serum titers in patients with endometriotic vs other benign ovarian cysts.ConclusionsCX3CL1 and CXCL1 are elevated in sera of EOC patients what points on their role in cancer development. Moreover, they might be useful in preoperative differential diagnosis of ovarian tumors, especially as they were not elevated in cases of endometriosis.

show abstract

Section: Discussionsupporting

confidence: 89%

Chemokine expression in patients with ovarian cancer or benign ovarian tumors

Nowak

Janas²,

Soja³

et al. 2021

Arch Med Sci

View full text Add to dashboard Cite

show abstract

“…CXCL1 levels in the endometrium are elevated in patients with endometriosis [201,202] and adenomyosis [203]. On the other hand, blood CXCL1 levels in patients with endometriosis are not altered [204]. Additionally, an increase in CXCL1 expression in the endometrium appears to only occur in some patients [205].…”

Section: Endometriosis and Adenomyosismentioning

confidence: 98%

The Importance of CXCL1 in the Physiological State and in Noncancer Diseases of the Oral Cavity and Abdominal Organs

Korbecki

Szatkowska

Kupnicka

et al. 2022

IJMS

View full text Add to dashboard Cite

CXCL1 is a CXC chemokine, CXCR2 ligand and chemotactic factor for neutrophils. In this paper, we present a review of the role of the chemokine CXCL1 in physiology and in selected major non-cancer diseases of the oral cavity and abdominal organs (gingiva, salivary glands, stomach, liver, pancreas, intestines, and kidneys). We focus on the importance of CXCL1 on implantation and placentation as well as on human pluripotent stem cells. We also show the significance of CXCL1 in selected diseases of the abdominal organs, including the gastrointestinal tract and oral cavity (periodontal diseases, periodontitis, Sjögren syndrome, Helicobacter pylori infection, diabetes, liver cirrhosis, alcoholic liver disease (ALD), non-alcoholic fatty liver disease (NAFLD), HBV and HCV infection, liver ischemia and reperfusion injury, inflammatory bowel disease (Crohn’s disease and ulcerative colitis), obesity and overweight, kidney transplantation and ischemic-reperfusion injury, endometriosis and adenomyosis).

show abstract

“…The published data from others and our own experience have shown that a disadvantage of the hypothesis-driven approach is that it normally focuses on a narrow aspect of the disease, which can often lead to a negative outcome. 34,38 For example, in the Cochrane Review by Gupta et al. 38 from 54 studies included in the systematic analysis, 31 studies evaluating 77 different biomarkers for endometriosis have shown negative outcome of initial hypothesis and could not distinguish women with and without endometriosis.…”

Section: Hypothesis-driven Biomarker Discoverymentioning

confidence: 99%

Challenges in uncovering non-invasive biomarkers of endometriosis

Hudson

Perricos

Wenzl

et al. 2020

Exp Biol Med (Maywood)

Self Cite

View full text Add to dashboard Cite

Endometriosis affects up to 10% of women of childbearing age, causing symptoms that can include chronic pelvic pain and reduced fertility. The symptoms are not specific to the disease and can be confused with other gynecological conditions or normal menstruation. Currently, the disease can be only definitively diagnosed by laparoscopy, as no clinically accepted biomarker exists. Biomarker discovery can either follow a hypothesis-driven approach selecting targets to be tested based on current knowledge of the disease, or take an unbiased high-throughput screening “omics” approach, such as transcriptomics or proteomics, to identify markers that are unique or elevated in accessible bodily fluids of patients with the disease. Numerous studies have been conducted using these approaches to try and identify endometriosis biomarkers, but variabilities in study design, cohort selection, and analysis, together with the fact that most studies were small-scale, have made independent validation of biomarker candidates difficult. Therefore, efforts are underway to standardize cohort selection, patient data, and sample collection to allow better cross-study comparisons. Large scale multi-center studies using this standardized approach are necessary to validate existing endometriosis biomarker candidates and uncover potential new markers. Given the complexity and heterogeneity of the disease, it is likely that a panel of biomarkers will be necessary to diagnose and categorize endometriosis. Impact statement Endometriosis is a common disease affecting reproductive age women, which is associated with chronic pain and reduced fertility reducing the quality of life of many women. Definitive diagnosis requires invasive laparoscopic surgery creating a high barrier to diagnosis that can delay the onset of treatment significantly. Clinically approved biomarkers of endometriosis are currently lacking, making the discovery and validation of biomarkers that would lead to earlier diagnosis a priority for improving treatment of the disease.

show abstract

The Serum Levels of the Soluble Factors sCD40L and CXCL1 Are Not Indicative of Endometriosis

Cited by 7 publications

References 29 publications

Chemokine expression in patients with ovarian cancer or benign ovarian tumors

Chemokine expression in patients with ovarian cancer or benign ovarian tumors

The Importance of CXCL1 in the Physiological State and in Noncancer Diseases of the Oral Cavity and Abdominal Organs

Challenges in uncovering non-invasive biomarkers of endometriosis

Contact Info

Product

Resources

About